Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
Portfolio Pulse from Vandana Singh
Sarepta Therapeutics' EMBARK Phase 3 study of Elevidys failed to meet the primary endpoint, leading to lowered price targets by Needham, RBC Capital, and Cantor Fitzgerald. Despite the trial miss, analysts believe Elevidys can maintain its existing label and continue marketing due to observed activity in key secondary endpoints. SRPT shares are down 40.3%.
October 31, 2023 | 6:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta's EMBARK Phase 3 trial miss led to lowered price targets by analysts. Despite this, Elevidys may maintain its existing label. SRPT shares are down 40.3%.
The failure of Sarepta's EMBARK Phase 3 trial has led to lowered price targets by analysts, indicating a negative short-term impact on the stock. However, the belief that Elevidys can maintain its existing label may mitigate some of this impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100